Challenges in Device Trials I’ve Faced

I’ve been working in medical device research for a few years now, and I’ve noticed that compliance with technical protocols can be a real hurdle in clinical trials. Recently, a trial I was involved in faced delays because the enrollment criteria were not as clear as they could have been. I’m curious if others have experienced similar issues and how you overcame them.

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‌⁠‌‍​⁠‌⁠​‍‌‍‍‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‌‌⁠‌⁠‌‌⁠⁠‌⁠‌​‌‍⁠⁠‌⁠​​‌‍‍‌‌‍​⁠​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​‍​‍‌‍⁠‍‌‍‌‌‌⁠‌⁠​‍​‍​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌​​⁠​‌​⁠​⁠​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌⁠‌‌‌‍​‍‌‍‌‍‌​‌⁠‌⁠‍​‌​‌⁠‌‍​‌‌‍‍⁠‌​⁠‌‌‌‍​‌‌‌‍​⁠‌‌‌‍‌‌‌‍‍​‌‌‌⁠‌‌‌⁠​‍​‍‌⁠⁠‌​

I totally get that! In my last trial, we improved clarity by holding a meeting with the team to go through the enrollment criteria together — having everyone on the same page made a big difference. Have you tried something similar?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‌⁠‌‍​⁠‌⁠​‍‌‍‍‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠‍‌​⁠‌‍​⁠‌​​⁠‌⁠​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌​​⁠​‌​⁠‌⁠​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌‌‌‌‌‍‍‍‌‌‍‍‌⁠‌‍‌​‍⁠‌​⁠‌‌‌​⁠‌​‌‍‌‍‌​‌⁠‌‌‌‌‌​‌⁠‍‌​⁠‍‌‌​⁠​‌⁠‍​‌⁠‍‌​‍​‍‌⁠⁠‌

It’s frustrating when those enrollment details are fuzzy; in one trial, we created a quick reference guide that outlined key criteria in plain language for the team. It was a game changer to keep everyone aligned. @sophia_martin89, have you thought about a similar approach?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‌⁠‌‍​⁠‌⁠​‍‌‍‍‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠‍‌​⁠‌‍​⁠‌​​⁠‌⁠​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌​​⁠​‌​⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌‌‍​‌⁠‌​‌‌‌⁠‌‍‌‍‌‍⁠⁠​⁠‌⁠‌⁠​‍‌⁠‌‌‌​‌‍​⁠​‌‌​‌‌‌‌​‌‌​⁠​‌​‌⁠‌‌‍​‌​‍‌​‍​‍‌⁠⁠‌

One thing that worked for me was using a flowchart to visualize the enrollment process — it really helped clarify the criteria for our team and potential participants. Have you tried incorporating visual aids like that, @agarcia?

‌⁠‍⁠​‍​‍‌⁠‌​​‍​‍​⁠‍‍​‍​‍‌‍‌⁠‌‍​⁠‌⁠​‍‌‍‍‍​‍​‍​‍⁠​​‍​‍‌‍‍⁠​‍​‍​⁠‍‍​‍​‍‌⁠​‍‌‍‌‌‌⁠​​‌‍⁠​‌⁠‍‌​‍​‍​‍⁠​​‍​‍‌‍‍‌‌‍‌​​‍​‍​⁠‍‍​⁠‍‌​⁠‌‍​⁠‌​​⁠‌⁠​‍⁠​​‍​‍‌‍‌​​‍​‍​⁠‍‍​‍​‍​⁠​‍​⁠​​​⁠​‍​⁠‌‍​⁠​​​⁠‌​​⁠​‍​⁠​⁠​‍​‍​‍⁠​​‍​‍‌‍‍​​‍​‍​⁠‍‍​‍​‍‌‍​⁠‌‌​​​‍⁠‌‌‍‌‌‌⁠​⁠‌‍​⁠‌​⁠‍‌⁠‌⁠‌‌​⁠‌​​‍​⁠‌⁠‌‌​‌‌⁠‍‌‌​‍‌‌⁠‌​‌​‌‍​‍​‍‌⁠⁠‌